



July 23, 2012

NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E)
MUMBAI -400 051

Dear Sirs,

SUB: Press Release – Reg
Ref: Our Company Code No. AUROPHARMA

Please find enclosed herewith a copy of Press Release issued by the Company.

This is for your information and record

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

A handwritten signature in black ink, appearing to read 'A. Mohan Ram Reddy'.

A. MOHAN RAMI REDDY
GM (Legal) & COMPANY SECRETARY

AUROBINDO PHARMA LTD

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 A.P., INDIA Tel : + + 91 40 6672 5000 Fax + + 91 40 2374 6833, 2374 1080

Corp. Off. : 'Auro House', 313, Bachupally, Outhubullapur (Mandal), RR District, Hyderabad - 500 072 A.P., INDIA Tel : + + 91 40 2304 4060-65 Fax + + 91 40 2304 4058 / 59

PAN No. AABCA7366H

www.aurobindo.com



23rd July 2012

**Aurobindo Pharma receives final approval for
Metformin Hydrochloride Extended Release Tablets**

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Metformin Hydrochloride Extended-Release (ER) Tablets USP 500mg and 750mg. (ANDA 079118). The product is ready for launch.

Metformin Hydrochloride ER Tablets USP 500mg and 750mg is the generic equivalent of Bristol Myers Squibb Company (BMS)'s Glucophage XR® Extended-release Tablets 500mg and 750mg respectively. Metformin Hydrochloride ER Tablets are oral anti-hyperglycemic drugs indicated as an adjunct to diet and exercise to improve glycemic control in patients with type-2 diabetes. The annual sale of the product is approximately US\$ 230 million.

The product has been approved out of Unit III formulations facility in Hyderabad, India

Aurobindo now has a total of 153 ANDA approvals (127 Final approvals including 1 from Aurolife Pharma LLC and 26 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com